Navigation Links
Amedica(R) Signs Joint Venture Agreement With Orthopaedic Synergy(R)
Date:2/22/2010

SALT LAKE CITY, Feb. 22 /PRNewswire/ -- Amedica Corporation (AC), a spinal and orthopaedic implant and instrument company focused on unique silicon nitride (SiN) ceramic technologies, announced today an agreement with Orthopaedic Synergy, Inc. (OSI), a holding company for OMNIlife Science™ and Enztec, both global designers, manufacturers and distributors of leading edge reconstructive surgery implants and instrumentation.

Amedica is a full-line spinal implant company that owns and markets silicon nitride ceramic technologies that are now being utilized in spinal implant applications; however, the unique SiN materials have disruptive characteristics for hip and knee implant applications, as well.  The material is fracture resistant; its bearing/articulating surfaces do not produce wear debris that is linked to osteolysis-related, re-operations.  Additionally, the implants are BioActive™ with a hydrophilic surface and a conductive cancellous structure to enhance bone in-growth and attachment.

The Joint Venture Development Agreement will allow the development, regulatory approval and distribution of SiN articulating hip and knee implants in the U.S. and abroad.  This agreement further secures both companies' competitive positions in the largest segment of orthopaedic care.

Orthopaedic Synergy is a global reconstructive hip and knee implant and instrument concern that designs, manufactures and distributes its products.  Its corporate headquarters is located in East Taunton, Mass., and its design, development and manufacturing center is based in Christchurch, New Zealand. OSI is known for leading-edge innovation, cost-effective, outcome-focused implant systems and deep orthopaedic executive management experience.  

"Amedica's SiN technology is ideally suited for the innovative modular hip and knee replacement products developed and marketed by our company, and we view this Joint Venture Development Agreement as a significant step forward in solving the issue of wear in reconstructive orthopaedic products," says Nik Nikolaev, Chairman and Chief Executive Officer of Orthopaedic Synergy, Inc.

"Finding the appropriate material to use as a bearing surface in Total Joint Arthroplasty has been an elusive goal, especially for Total Hip Replacement. We have been investigating alternate materials for some time, and we are convinced that Amedica's  SiN technology is the answer. We are proud that they chose OSI to be their partner," says George Cipolletti, President of OMNIlife Science.  

"We are pleased that this agreement is now in place.  SiN is a disruptive human implant material that has application in spine, reconstructive surgery and other orthopaedic implant indications.  We are honored to be in this relationship with Orthopaedic Synergy – it is truly an alliance that, in time, can clearly enhance patient outcomes," says Ben Shappley, Chief Executive Officer, President and Director of Amedica.

About Orthopaedic Synergy:

Orthopaedic Synergy, Inc. is a global reconstructive orthopaedic concern that functions as a holding company for OMNIlife Science, Inc. and Enztec, Ltd.  The Company designs, develops and distributes FDA cleared and CE approved reconstructive orthopaedic implants that represent leading edge technologies.

About Amedica:

Amedica Corporation is ISO 13485 certified and its products are FDA cleared and CE approved.  Amedica Corporation is an emerging orthopaedic implant company focused on using its silicon nitride ceramic technologies to develop and commercialize a broad range of innovative, unique spine and total joint implants for the growing orthopaedic device market.  It has brought to market various spinal implant products, while products under development include reconstructive hip and knee implants that represent a new standard of care in total joint implants based on superior performance, safety and efficacy.

SOURCE Amedica Corporation

Back to top

RELATED LINKS
http://www.amedicacorp.com

'/>"/>

SOURCE Amedica Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
2. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
3. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
4. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
5. New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema
6. ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science
7. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
8. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
9. CellCyte Genetics Signs Collaborative Agreement With Northwestern Universitys Feinberg School of Medicine to Perform Disease Model Outcome Study of CellCytes CCG-TH30 Product Candidate
10. Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
11. ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... ambulance transport experience for the millions of people who require these medical transport ... taxi industry through the use of technology. Now, SmartEMS has put forth an ...
(Date:6/26/2016)... ... , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... a whole new perspective by using the title layers in ProSlice Levels to ... ProSlice Levels contains over 30 Different presets to choose from. FCPX users ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... ... , ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter ... bar too high can result in disappointment, perhaps even self-loathing. However, those who set ... , Research from PsychTests.com reveals that behind the tendency to set low ...
Breaking Medicine News(10 mins):